The estimated Net Worth of Nancy Lurker is at least $4.37 Million dollars as of 16 August 2024. Ms. Lurker owns over 3,173 units of EyePoint Pharmaceuticals Inc stock worth over $802,560 and over the last 11 years she sold EYPT stock worth over $1,491,000. In addition, she makes $2,079,780 as President, Chief Executive Officer, and Director at EyePoint Pharmaceuticals Inc.
Nancy has made over 23 trades of the EyePoint Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently she bought 3,173 units of EYPT stock worth $25,003 on 16 August 2024.
The largest trade she's ever made was exercising 137,174 units of EyePoint Pharmaceuticals Inc stock on 21 February 2020 worth over $1,127,570. On average, Nancy trades about 18,379 units every 52 days since 2013. As of 16 August 2024 she still owns at least 97,635 units of EyePoint Pharmaceuticals Inc stock.
You can see the complete history of Ms. Lurker stock trades at the bottom of the page.
Nancy S. Lurker serves as President, Chief Executive Officer, Director of the Company. She served as President and Chief Executive Officer and a director of PDI, Inc., a NASDAQ-listed healthcare commercialization company now named Interpace Diagnostics Group, Inc. From 2006 to 2007, Ms. Lurker was Senior Vice President and Chief Marketing Officer of Novartis Pharmaceuticals Corporation, the U.S. subsidiary of Novartis AG. From 2003 to 2006, she served as President and Chief Executive Officer of ImpactRx, Inc., a privately held healthcare information company. From 1998 to 2003, Ms. Lurker served as Group Vice President, Global Primary Care Products and Vice President, General Therapeutics for Pharmacia Corporation (Pharmacia), now a part of Pfizer, Inc. She also served as a member of Pharmacia’s U.S. executive management committee. Previously, Ms. Lurker spent 14 years at Bristol-Myers Squibb Company, rising from a sales representative to Senior Director, Worldwide Cardiovascular Franchise Management. Ms. Lurker serves as chair of the board of directors of X4 Pharmaceuticals, Inc. and as a member of the board of directors of the Cancer Treatment Centers of America, both privately held companies. Ms. Lurker previously served as a member of the boards of directors of publicly held Auxilium Pharmaceuticals, Inc. from 2011 to 2015 and Mallinckrodt Pharmaceuticals, plc from 2013 to 2016, in addition to serving as a director of PDI, Inc. from 2008 to 2015. Ms. Lurker received a B.S. in Biology from Seattle Pacific University and an M.B.A. from the University of Evansville. Ms. Lurker’s role as President and Chief Executive Officer of the Company, as well as her broad ranging experience in the pharmaceutical industry and her track record of maximizing the potential of new therapies and successfully implementing innovative U.S.
As the President, Chief Executive Officer, and Director of EyePoint Pharmaceuticals Inc, the total compensation of Nancy Lurker at EyePoint Pharmaceuticals Inc is $2,079,780. There are no executives at EyePoint Pharmaceuticals Inc getting paid more.
Nancy Lurker is 62, she's been the President, Chief Executive Officer, and Director of EyePoint Pharmaceuticals Inc since 2016. There are 7 older and 9 younger executives at EyePoint Pharmaceuticals Inc. The oldest executive at EyePoint Pharmaceuticals Inc is Goran Ando, 71, who is the Independent Chairman of the Board.
Nancy's mailing address filed with the SEC is C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, WATERTOWN, MA, 02472.
Over the last 6 years, insiders at EyePoint Pharmaceuticals Inc have traded over $67,100,515 worth of EyePoint Pharmaceuticals Inc stock and bought 21,910,863 units worth $111,404,456 . The most active insiders traders include Healthcare Partners, L.P.Ew..., Asset Management, Lp Chen B..., and Ye Liu. On average, EyePoint Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $1,746,068. The most recent stock trade was executed by Goran Ando on 21 August 2024, trading 5,000 units of EYPT stock currently worth $39,750.
psivida corp., (nasdaq: psdv) (asx: pva) headquartered in watertown, ma, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. psivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, durasert™ and biosilicon™. the injectable, sustained release micro-insert iluvien® for the treatment of chronic diabetic macula edema (dme), licensed to alimera sciences, inc., has received marketing authorization in austria, france, germany, portugal, the u.k. spain, and italy. iluvien for dme has recently been approved in the us. psivida plans to institute pivotal phase iii clinical trials for the treatment of posterior uveitis with the same micro-insert as iluvien for dme. an investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension. psivida's two fda-approved products, retisert®
EyePoint Pharmaceuticals Inc executives and other stock owners filed with the SEC include: